Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
An injectable version of the drug, currently given by intravenous infusion, is under U.S. regulatory review.
The best results were seen in people who started treatment while in the earliest stages of the brain-wasting disease.
In a pivotal trial of patients with early-stage Alzheimer's, Leqembi was shown to slow cognitive decline by 27% compared to a placebo after 18 months - data that supported the drug's U.S. approval in 2023.
The companies continued to follow about 95% of patients enrolled in that trial. The latest results show that after four years, Leqembi slowed cognitive decline by 34% compared to what would be expected in similar patients who did not receive treatment.
Leqembi targets protofibrils - toxic building blocks that eventually form clumps in the brain known as amyloid plaques, a hallmark of Alzheimer's disease.
There were no new safety findings over the four-year period. Brain swelling and bleeding associated with drugs that work by removing amyloid plaque from the brain largely occurred within the first six months of treatment, according to data presented at the Alzheimer's Association International Conference in Toronto.
More than 50% of patients who started treatment in the earlier stages of Alzheimer's continued to show improvement in clinical scores after four years on Leqembi.
Eisai is conducting a separate study of Leqembi in pre-symptomatic Alzheimer's patients that is due to conclude in late 2027. Eli Lilly (LLY.N), opens new tab is also studying its Alzheimer's drug Kisunla in people who have detectable disease pathology, but show no noticeable cognitive decline.
The U.S. Food and Drug Administration, where recent job cuts have raised questions about review times, is slated to decide by August 31 whether to approve an injectable version of Leqembi that could be given to patients at home or at medical facilities.
Lynn Kramer, Eisai's chief clinical officer, said interactions with the FDA "have been right on schedule. They have been communicating with us all the time in an expected manner."
He said the new formulation "will be very helpful to starting new patients" on the drug, which is continuing to see "escalating usage."
Eisai will report its latest quarterly results next week, while Biogen will report results on Thursday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
10 minutes ago
- The Independent
Doctors decry RFK Jr decision to slash mRNA vaccine grants: ‘Our nation will pay in lives'
Doctors are sounding the alarm about potentially deadly consequences of the Trump administration's decision to slash $500 million in funding for mRNA vaccine development, saying the 'deeply troubling' move could leave Americans defenseless in the face of a biological attack, or another pandemic. Leading physicians and vaccine specialists were among the medical and scientific experts who told The Independent that years of progress had been lost, including the lessons learned during Covid. 'This is a deeply troubling development that will, in the short term, leave the U.S. poorly prepared for a pandemic or biological attack, and, in the long term, stifle medical innovation upon which so many Americans depend for life saving cures,' Dr. Jennifer Nuzzo, director of the Pandemic Center at the Brown University School of Public Health, said in an email. Health and Human Services Sec. Robert F Kennedy Jr announced Tuesday the termination of 22 projects, including contracts with Emory University and Covid shot-makers Moderna, Pfizer, and AstraZeneca. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,' Kennedy said. While Kennedy, who has questioned Covid vaccine safety and previously falsely claimed the measles vaccine contains fetal debris, cited a review of 'the science' in terminating the project. But Dr Nuzzo said the 'attack on mRNA vaccine technology rests on phony and false claims, proven so by real facts and evidence'. She continued: 'It is, however, aligned with his long-held and deadly determination to sow doubts about all vaccines and to restrict the ability of the American people to access vaccines. Our nation will pay dearly for this decision in dollars and lives.' The mRNA vaccines work differently from traditional vaccines, which inject a weakened virus into the body to trigger an immune response. Instead, mRNA vaccines teach the cells to make small and harmless pieces of virus that trigger the same response. The anti-vaxxer movement and Kennedy have inaccurately claimed that mRNA Covid vaccines are deadly and that vaccines 'poisoned' American children but they are safe according to decades of public research and countless government assessments. The only mRNA vaccines currently available are Covid vaccines. They were able to be brought to market so quickly because scientists didn't need the virus to make them, and the vaccine material can be created in a lab. Research also has been underway to produce mRNA vaccines against cancer and other infectious diseases, work that has been going on for decades. 'While most would associate mRNA vaccine technology with Covid, it was in development for over half a century and the U.S. government's partnership in that development goes back decades,' Richard Hughes IV, a former vice president of public policy at mRNA vaccine manufacturer Moderna who teaches vaccine law at George Washington University Law School, told The Independent. 'These kinds of partnerships are what drive innovation and save us from public health emergencies. When we lose this kind of progress, we create future public health risks.' Scientists know it's only a matter of time before the next pandemic, when vaccines may once again be needed en masse. Dr. Jake Scott, an infectious diseases physician and Clinical Associate Professor at Stanford University School of Medicine, said that no other vaccine technology could provide the world with a vaccine as quickly as is need during a pandemic. He noted that Kennedy's decision was rewriting the history of the pandemic and the lifesaving track record of mRNA vaccines. 'Vaccines aren't some niche drug. We're not talking about some rare skin cancer drug. We're talking about medicines that apply to literally every human being on the planet and we should have learned from the Covid pandemic that everyone is potentially susceptible to pandemic,' Dr Scott said. In what experts have labeled an assault on science, the Trump administration has eliminated grants and dramatically reduced the workforce of federal health and science agencies. Theses actions, and Kennedy's mRNA cuts, are likely in response to government vaccine mandates and restrictions, Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, told The Independent. 'It's a tremendous step backward, the is politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,' he said.
Reuters
10 minutes ago
- Reuters
US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies
Aug 6 (Reuters) - Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of conspiring to restrict drug discounts offered to community pharmacies that contract with providers serving low-income patients. A three-judge panel of the 2nd U.S. Circuit Court of Appeals in New York ruled, opens new tab that federally funded Mosaic Health and Central Virginia Health Services can move ahead for now with their proposed class action. The appeals court in its unanimous order reversed a decision by a federal judge dismissing the lawsuit. The clinics contend the drugmakers schemed in 2020 to limit discounts on diabetes drugs that were available to safety-net providers purchasing drugs from some pharmacies through a federal program known as "340B." As direct competitors, the four defendants control the diabetes drug marketplace, which would make imposing restrictions "easy to coordinate and maintain,' Circuit Judge Myrna Pérez wrote in the ruling, joined by Circuit Judges Alison Nathan and Maria Araújo Kahn. A Sanofi spokesperson in a statement said the company was reviewing the opinion and considering its next steps. Eli Lilly, Novo Nordisk and AstraZeneca did not immediately respond to requests for comment. The companies have denied any wrongdoing. Brian Feldman, a lead attorney for the health clinics, in a statement called the 2nd Circuit's order a 'watershed moment' and said 'we look forward to seeking justice for safety-net providers.' Mosaic Health operates 22 clinics in New York, and Central Virginia Health Services runs 18 clinics in Virginia. The two clinics sued in 2021 seeking damages for alleged revenue lost from the discount program's savings. The plaintiffs told the appeals court that Sanofi and the other manufacturers made billions of dollars in additional profits 'at the expense of safety-net providers and, ultimately, the patients they serve.' In a court filing, the drugmakers called the plaintiffs' claims 'far-fetched' and said the clinics were trying to punish the companies for implementing policies designed to address what they said were 'well-documented' abuses of the 340B program. Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid. The case is Mosaic Health Inc v. Sanofi-Aventis U.S. LLC et al, 2nd U.S. Circuit Court of Appeals, No. 24-598. For plaintiffs: Brian Feldman of Aurelian Law For defendants: Allon Kedem of Arnold & Porter Kaye Scholer Read more: Wegovy maker Novo hit with investor class action over revenue forecast cut AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action Mylan to pay $73.5 mln to settle drug wholesalers' EpiPen antitrust claims US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit
The Independent
13 minutes ago
- The Independent
Trump once hailed mRNA vaccines as a 'medical miracle.' Now RFK Jr. is halting advancement
President Donald Trump hailed as a 'medical miracle' the mRNA vaccines developed to combat the deadly COVID-19 pandemic in 2020. Now, his health secretary Robert F. Kennedy Jr., is effectively halting the vaccine technology's advancement. Kennedy announced Tuesday that the federal government is canceling $500 million worth of mRNA research development contracts, putting an end to U.S.-backed hopes for the vaccine technology to prevent future pandemics, treat cancer or prevent flu infections. It's a sharp pivot from how Trump and top officials described the technology during his first term. Here's a look at what Trump and some of his closest advisers have said about mRNA vaccines that were credited with slowing the pandemic five years ago. Robert Redfield, Trump's director of the Center's for Disease Control 'A COVID-19 vaccine is the thing that will get Americans back to normal everyday life,' said Redfield, in a Sept. 16, 2020 statement. Americans were still donning face masks as one of the few ways of protecting themselves from a virus that had killed nearly 200,000 in just over six months. Redfield promised that the new vaccines — developed for the first time using mRNA technology — would offer a return to normalcy. Trump wanted to make sure Biden didn't get credit 'Don't let Joe Biden take credit for the vaccines ... because the vaccines were me, and I pushed people harder than they've ever been pushed before .. The vaccines are — there are those that say it's one of the greatest things. It's a medical miracle.' Trump said on Nov. 26, 2020 said during a news conference in the White House. Weeks earlier, Trump had lost the election in a bitter race against Democrat Joe Biden. As the Republican grappled with leaving Washington and continued to plan for the rollout of the COVID-19 vaccines, he reminded reporters that he oversaw the development of the new shots. 'They say it's somewhat of a miracle and I think that's true,' Trump said on Dec. 8, 2020 during a speech at the Eisenhower Executive Office Building. The event celebrated 'Operation Warp Speed," the government-funded project that accelerated vaccine development with pharmaceutical companies. Trump was promoting the shots as the government prepared to offer them to frontline health workers. Trump's first-term health secretary, Alex Azar 'It's clear that many Americans are learning these vaccines are safe and extraordinarily effective,' Azar said on Dec. 16, 2020 at a news conference. The government was shipping out mRNA vaccines to states, preparing to distributed it to the masses. Azar noted that a vast majority of Americans — between 70% to 80%, according to polls — intended to get the new COVID-19 vaccine that would be available to the public in the coming months. Gen. Gusave Perna, Trump's chief operating officer for pandemic response 'It takes somewhere between five and 10 years to put a vaccine on the street. Look what we did. Now, that's because of the great work of the scientists who had done the research on mRNA vaccines and others because of industry working on this, they just didn't wake up one day and start working on it,' Perna said during a podcast interview that aired on May 9, 2023. Reflecting in an interview about his time overseeing 'Operation Warp Speed,' Perna credited the mRNA technology with the government's ability to get shots in arms mere months after the pandemic started claiming lives in the U.S. in 2020. Trump supporters boo his vaccine accomplishments 'Take credit because we saved tens of millions of lives. Take credit. Don't let them take that away from you,' Trump said on Dec. 19, 2021 during a live interview with former Fox News host Bill O'Reilly. Daily COVID-19 deaths had ticked down to 1,500 compared to 3,000 from a year earlier after Americans began receiving their first doses of the mRNA vaccines. Trump revealed to O'Reilly and the audience that he had just gotten a COVID-19 booster. The crowd booed.
